Zebin Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11182197/publications.pdf Version: 2024-02-01



ZERIN WANC

#	Article	IF	CITATIONS
1	Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer. Cancer Cell, 2013, 24, 213-228.	16.8	678
2	FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO Journal, 2009, 28, 2908-2918.	7.8	204
3	FoxM1 Mediates Resistance to Herceptin and Paclitaxel. Cancer Research, 2010, 70, 5054-5063.	0.9	152
4	Deregulation of FoxM1b leads to tumour metastasis. EMBO Molecular Medicine, 2011, 3, 21-34.	6.9	127
5	<i>FoxM1</i> in Tumorigenicity of the Neuroblastoma Cells and Renewal of the Neural Progenitors. Cancer Research, 2011, 71, 4292-4302.	0.9	80
6	Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features. Journal of Hepatology, 2015, 63, 429-436.	3.7	71
7	FoxM1 Regulates Mammary Luminal Cell Fate. Cell Reports, 2012, 1, 715-729.	6.4	60
8	Protein Tyrosine Kinase 6 Directly Phosphorylates AKT and Promotes AKT Activation in Response to Epidermal Growth Factor. Molecular and Cellular Biology, 2010, 30, 4280-4292.	2.3	57
9	PTK6 Activation at the Membrane Regulates Epithelial–Mesenchymal Transition in Prostate Cancer. Cancer Research, 2013, 73, 5426-5437.	0.9	39
10	Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. Cancer Research, 2018, 78, 6691-6702.	0.9	36
11	PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget, 2014, 5, 6038-6048.	1.8	26
12	Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma. Molecular Cancer Therapeutics, 2013, 12, 759-767.	4.1	20
13	PARP6 inhibition as a strategy to exploit centrosome clustering in cancer cells?. Oncotarget, 2019, 10, 690-691.	1.8	3